Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) Products under Development by Stage of Development | 7 | 1 |
| Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) Products under Development by Therapy Area | 8 | 1 |
| Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) Products under Development by Indication | 9 | 1 |
| Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) Pipeline Products Glance | 10 | 2 |
| Late Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) Products under Development by Companies | 12 | 2 |
| Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) Products under Development by Universities/Institutes | 14 | 2 |
| Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) Therapeutics Assessment | 16 | 5 |
| Assessment by Monotherapy/Combination Products | 16 | 1 |
| Assessment by Mechanism of Action | 17 | 2 |
| Assessment by Route of Administration | 19 | 1 |
| Assessment by Molecule Type | 20 | 1 |
| Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) Companies Involved in Therapeutics Development | 21 | 7 |
| Addex Therapeutics Ltd | 21 | 1 |
| Denovo Biopharma, LLC | 22 | 1 |
| Domain Therapeutics SA | 23 | 1 |
| Eli Lilly and Company | 24 | 1 |
| Medgenics, Inc. | 25 | 1 |
| Prexton Therapeutics SA | 26 | 1 |
| Taisho Pharmaceutical Holdings Co., Ltd. | 27 | 1 |
| Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) Drug Profiles | 28 | 11 |
| DT-011088 Drug Profile | 28 | 1 |
| fasoracetam Drug Profile | 29 | 2 |
| LY-341495 Drug Profile | 31 | 1 |
| MGS-0028 Drug Profile | 32 | 1 |
| pomaglumetad methionil Drug Profile | 33 | 2 |
| Small Molecules to Agonize mGluR3 for Parkinson's Disease Drug Profile | 35 | 1 |
| Small Molecules to Antagonize mGluR3 for Anxiety and Depression Drug Profile | 36 | 1 |
| Small Molecules to Modulate mGlu3 Receptor for CNS Disorders Drug Profile | 37 | 1 |
| VU-0092273 Drug Profile | 38 | 1 |
| Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) Dormant Projects | 39 | 3 |
| Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) Discontinued Products | 42 | 1 |
| Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) Featured News &Press Releases | 43 | 4 |
| Jun 17, 2016: Medgenics Announces Enrollment of First Patient in Phase 2/3 Clinical Trial of NFC-1 in Adolescents With mGluR Mutation Positive ADHD | 43 | 1 |
| Apr 14, 2014: Domain Therapeutics continues program to alter course of Parkinson s disease with renewed support by The Michael J. Fox Foundation | 43 | 1 |
| Aug 29, 2012: Lilly Stops Phase III Development Of Pomaglumetad Methionil For Treatment Of Schizophrenia Based On Efficacy Results | 43 | 1 |
| Jul 11, 2012: Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint Of Clinical Study | 44 | 1 |
| Mar 29, 2009: Lilly Announces Inconclusive Phase II Study Results For mGlu2/3 At The International Congress On Schizophrenia Research | 45 | 1 |
| Sep 02, 2007: Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds | 45 | 2 |
| Appendix | 47 | 2 |
| Methodology | 47 | 1 |
| Coverage | 47 | 1 |
| Secondary Research | 47 | 1 |
| Primary Research | 47 | 1 |
| Expert Panel Validation | 47 | 1 |
| Contact Us | 47 | 1 |
| Disclaimer | 48 | 1 |
